Program
Anti-CDH6 Antibody-drug Conjugate SIM0505
Its studies are mostly in Fallopian Tube Neoplasms, led by NextCure.
Furthest: phase 1, since Jan 13, 20251 company-led study, 1 open or runningNext primary completion: Feb 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NextCure | 11 open or running | phase 1since Jan 13, 2025 | Jan 13, 2025 | Feb 2028phase 1 · NCT06792552 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 13, 2025First study: phase 1 study in Fallopian Tube NeoplasmsFirst studyNCT06792552 · 738 planned · United States, China
Ahead
- Feb 2028Primary completion: phase 1 study in Fallopian Tube NeoplasmsNCT06792552
TargetBeta
CDH6 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6; K-cadherin) ”NCIt, by rule
Other programs on CDH6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| raludotatug deruxtecan | Merck | phase 3 | 11 |
| TJ102rule | phrontline-biopharma | phase 2 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06792552Fallopian Tube Neoplasms · United States, China | 1 | Recruiting | Feb 2028 | 738 |
How it is read
Names in the registry
- “SIM0505 for injection”, 2 entries
Conditions, from the studies’ own filings
- Fallopian Tube Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.